{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:34:09Z","timestamp":1758944049878},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.leukres.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,21]],"date-time":"2016-02-21T23:31:45Z","timestamp":1456097505000},"page":"1-8","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy"],"prefix":"10.1016","volume":"43","author":[{"given":"Edward","family":"Pearson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smeet","family":"Gala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Nieset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merena","family":"Nanavaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mkaya","family":"Mwamburi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2016.02.001_bib0005","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.1998.16.9.2897","article-title":"Initial therapy for chronic myelogenous leukemia: playing the odds","volume":"16","author":"Lee","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2016.02.001_bib0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clinl. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2016.02.001_bib0015","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2016.02.001_bib0020","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2016.02.001_bib0025","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.leukres.2016.02.001_bib0030","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2016.02.001_bib0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","article-title":"Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors","volume":"39","author":"Lipton","year":"2015","journal-title":"Leukemia Res."},{"issue":"1","key":"10.1016\/j.leukres.2016.02.001_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2012","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.leukres.2016.02.001_bib0045","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2016.02.001_bib0050","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2016.02.001_bib0055","first-page":"16","article-title":"Integrating current treatment options for TKI-resistant chronic myeloid leukemia: general discussion","volume":"12","author":"Radich","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol.: H&O."},{"issue":"8","key":"10.1016\/j.leukres.2016.02.001_bib0060","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/phar.1266","article-title":"Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"33","author":"Irvine","year":"2013","journal-title":"Pharmacother.: J. Hum. Pharmacol. Drug Ther."},{"issue":"2","key":"10.1016\/j.leukres.2016.02.001_bib0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.leukres.2016.02.001_bib0070","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.001_bib0075","first-page":"163","volume":"2012","author":"Cortes","year":"2012","journal-title":"ASH Annu. Meeting Abstracts"},{"issue":"12","key":"10.1016\/j.leukres.2016.02.001_bib0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","article-title":"Group EBotCCBR: updated method guidelines for systematic reviews in the cochrane collaboration back review group","volume":"28","author":"Van Tulder","year":"2003","journal-title":"Spine"},{"issue":"6","key":"10.1016\/j.leukres.2016.02.001_bib0085","first-page":"1","article-title":"Deaths: preliminary data for 2011","volume":"61","author":"Hoyert","year":"2012","journal-title":"Natl. Vital Stat. Rep."},{"issue":"6","key":"10.1016\/j.leukres.2016.02.001_bib0090","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.leukres.2016.02.001_bib0095","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.leukres.2016.02.001_bib0100","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.001_bib0105","article-title":"Using of dasatinib for treatment imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in chronic phase. russian experience of dasatinib treatment","author":"Khoroshko","year":"2010","journal-title":"Haematol. J."},{"issue":"9","key":"10.1016\/j.leukres.2016.02.001_bib0110","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","article-title":"Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant\/intolerant to imatinib","volume":"35","author":"Latagliata","year":"2011","journal-title":"Leukemia Res."},{"issue":"9","key":"10.1016\/j.leukres.2016.02.001_bib0115","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2016.02.001_bib0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2016.02.001_bib0125","first-page":"2013","article-title":"Imatinib dose hike in suboptimal response and failure in CML CP: results from a developing nation","author":"Gullipalli","year":"2013","journal-title":"J. Clin. Oncol. : Am. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2016.02.001_bib0130","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3324\/haematol.2011.060087","article-title":"High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients\u2013final analysis of a randomized, multicenter, phase III trial","volume":"97","author":"Petzer","year":"2012","journal-title":"Haematologica."},{"issue":"18","key":"10.1016\/j.leukres.2016.02.001_bib0135","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400\u2013600mg daily","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.02.001_bib0140","first-page":"01","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-Study IV","author":"Sau\u00dfele","year":"2016","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T17:04:43Z","timestamp":1567616683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":28,"alternative-id":["S0145212616300169"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}